PANORAMA Helps Regeneron's Eylea Even Score With Roche's Lucentis
Phase III PANORAMA looks good, so far, for Regeneron's Eylea in diabetic retinopathy without edema.
You may also be interested in...
The latest drug development news and highlights from our US FDA Performance Tracker.
Regeneron's workhorse blockbuster Eylea has scored another indication for diabetic retinopathy, as the company braces for new competition from Novartis later this year.
Regeneron promised big things for PD-1 inhibitor cemiplimab during its first quarter earnings call, including studies to test its potential in lung cancer compared to Merck's Keytruda. It hopes to launch the antibody in a smaller indication later this year.